TSC1
MCID: TBR024
MIFTS: 63

Tuberous Sclerosis-1 (TSC1) malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Eye diseases, Nephrological diseases, Skin diseases, Fetal diseases

Aliases & Classifications for Tuberous Sclerosis-1

About this section
Sources:
12diseasecard, 23GeneReviews, 24GeneTests, 25Genetics Home Reference, 27GTR, 31ICD10 via Orphanet, 37MedGen, 39MeSH, 40MESH via Orphanet, 48NIH Rare Diseases, 52OMIM, 54Orphanet, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Tuberous Sclerosis-1:

Name: Tuberous Sclerosis-1 52 12
Tuberous Sclerosis Complex 23 24 25 54 70
Bourneville Syndrome 48 54 70
Bourneville Disease 23 24 25
Tuberous Sclerosis 54 70 68
Tuberous Sclerosis, Type 1 48 27
Tuberous Sclerosis 1 70 68
Epiloia 24 25
Bourneville Pringle Syndrome 24
 
Bourneville Phakomatosis 25
Bourneville's Syndrome 48
Bourneville's Disease 24
Sclerosis Tuberosa 25
Cerebral Sclerosis 25
Tuberose Sclerosis 25
Phakomatosis Ts 24
Tsc1 70
Ts 70

Characteristics:

Orphanet epidemiological data:

54
tuberous sclerosis complex:
Inheritance: Autosomal dominant; Prevalence: 1-9/1000000 (United States),1-5/10000 (Europe),1-9/100000 (Ireland),1-9/100000 (United Kingdom),1-5/10000 (United Kingdom),1-9/100000 (United States),1-9/100000 (Taiwan, Province of China); Age of onset: All ages; Age of death: any age

HPO:

64
tuberous sclerosis-1:
Inheritance: autosomal dominant inheritance, heterogeneous
Onset and clinical course: phenotypic variability

GeneReviews:

23
Penetrance: after detailed evaluation of each individual known to have a tsc1 or tsc2 pathogenic variant, the penetrance of tsc is now thought to be 100%. rare instances of apparent non-penetrance have been reported; however, molecular studies revealed the presence of two different pathogenic variants in the family and the existence of germline mosaicism in others [connor et al 1986, webb & osborne 1991, rose et al 1999]...


Classifications:



External Ids:

OMIM52 191100
Orphanet54 ORPHA805
ICD10 via Orphanet31 Q85.1
MESH via Orphanet40 D014402
UMLS via Orphanet69 C0041341
MeSH39 D014402

Summaries for Tuberous Sclerosis-1

About this section
OMIM:52 Tuberous sclerosis complex (TSC) is an autosomal dominant multisystem disorder characterized by hamartomas in multiple... (191100) more...

MalaCards based summary: Tuberous Sclerosis-1, also known as tuberous sclerosis complex, is related to tuberous sclerosis and polycystic kidney disease, infantile severe, with tuberous sclerosis, and has symptoms including back pain, headache and pain. An important gene associated with Tuberous Sclerosis-1 is TSC1 (Tuberous Sclerosis 1), and among its related pathways are LKB1 signaling events and Wnt Signaling Pathway Netpath. Affiliated tissues include skin, kidney and brain, and related mouse phenotypes are Decreased sensitivity to paclitaxel and Decreased viability with paclitaxel.

Genetics Home Reference:25 Tuberous sclerosis complex is a genetic disorder characterized by the growth of numerous noncancerous (benign) tumors in many parts of the body. These tumors can occur in the skin, brain, kidneys, and other organs, in some cases leading to significant health problems. Tuberous sclerosis complex also causes developmental problems, and the signs and symptoms of the condition vary from person to person.

UniProtKB/Swiss-Prot:70 Tuberous sclerosis 1: An autosomal dominant multi-system disorder that affects especially the brain, kidneys, heart, and skin. It is characterized by hamartomas (benign overgrowths predominantly of a cell or tissue type that occurs normally in the organ) and hamartias (developmental abnormalities of tissue combination). Clinical manifestations include epilepsy, learning difficulties, behavioral problems, and skin lesions. Seizures can be intractable and premature death can occur from a variety of disease-associated causes.

GeneReviews for NBK1220

Related Diseases for Tuberous Sclerosis-1

About this section

Diseases in the Tuberous Sclerosis family:

tuberous sclerosis-1

Diseases related to Tuberous Sclerosis-1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 63)
idRelated DiseaseScoreTop Affiliating Genes
1tuberous sclerosis12.7
2polycystic kidney disease, infantile severe, with tuberous sclerosis12.2
3sudanophilic cerebral sclerosis12.0
4cerebral sclerosis similar to pelizaeus-merzbacher disease11.8
5gilles de la tourette syndrome11.7
6turner syndrome11.6
7adrenoleukodystrophy11.2
8metachromatic leukodystrophy11.1
9tsc2 angiomyolipomas, renal, modifier of11.1
10trichostasis spinulosa11.0
11mitochondrial dna depletion syndrome 4a11.0
12tumefactive multiple sclerosis11.0
13timothy syndrome10.9
14pelizaeus-merzbacher disease10.8
15albinism, oculocutaneous, type ib10.7
16spermatogenic failure 1010.3PKD1, TSC2
17bruck syndrome10.3NF1, PKD1
18hemolytic anemia due to adenylate kinase deficiency10.3MTOR, TSC1
19chronic polyneuropathy10.2CCL26, TSC1, TSC2
20aids - neurological complications10.2DCX, TSC1, TSC2
21chromosome 18p tetrasomy10.2PKD1, TSC2
22herpes simplex encephalitic 610.2PTEN, TSC1, TSC2
23polycythemia10.2MTOR, TSC1, TSC2
24multiple mitochondrial dysfunctions syndrome 110.2CCL26, PTEN, TSC1, TSC2
25gallbladder cancer10.2MTOR, TSC1, TSC2
26childhood teratocarcinoma of the testis10.2PTEN, TSC1, TSC2
27diabetes hypogonadism deafness mental retardation10.2GFAP, SYP
28melorheostosis with osteopoikilosis10.2TSC1, TSC2
29papillary tumor of the pineal region10.2GFAP, SYP
30superior vena cava syndrome10.2GFAP, SYP, TSC2
31charcot-marie-tooth disease, type 1c10.2PKD1, PKHD1, TSC2
32behcet's syndrome arthropathy10.2DBH, GFAP, SYP
33neurological consequences of cytomegalovirus infection10.2MTOR, PTEN, TSC1
34epidermal appendage tumor10.2GFAP, PTEN, SYP
35aneurysm of sinus of valsalva10.2GFAP, PTEN, SYP
36cervical adenoid cystic carcinoma10.2GFAP, NF1
37postgastrectomy syndrome10.1NF1, SYP
38gangliosidosis gm110.1CCL26, MTOR, TSC1, TSC2
39anemia, hemolytic, rh-null, regulator type10.1PKD1, PKHD1, TSC2
40central neurocytoma10.1GFAP, NF1, SYP
41early myoclonic encephalopathy10.1GFAP, PTEN, SYP
42inner ear cancer10.1GFAP, SYP, TSC1, TSC2
43pharynx cancer10.1GFAP, NF1, SYP
44central nervous system hemangioma10.1GFAP, NF1, SYP
45brain stem ependymoma10.1GFAP, SYP
46bartter disease10.1DCX, NF1, PTEN, TSC2
47kidney papillary necrosis10.1PKD1, PKHD1, TSC2
48psoriasis susceptibility 1310.0MTOR, PKD1, PKHD1, TSC1
49glomeruloid hemangioma10.0GFAP, NF1, PTEN, SYP
50spinocerebellar ataxia, autosomal recessive 210.0MTOR, RPS6KB1, TSC1, TSC2

Graphical network of the top 20 diseases related to Tuberous Sclerosis-1:



Diseases related to tuberous sclerosis-1

Symptoms & Phenotypes for Tuberous Sclerosis-1

About this section

Symptoms by clinical synopsis from OMIM:

191100

Clinical features from OMIM:

191100

Human phenotypes related to Tuberous Sclerosis-1:

 54 64 (show all 67)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal insufficiency64 54 Occasional (29-5%) HP:0000083
2 gingival fibromatosis64 54 Occasional (29-5%) HP:0000169
3 gingivitis64 54 Occasional (29-5%) HP:0000230
4 prominent occiput64 54 Very frequent (99-80%) HP:0000269
5 iris coloboma64 54 Occasional (29-5%) HP:0000612
6 optic atrophy64 54 Frequent (79-30%) HP:0000648
7 behavioral abnormality64 54 Frequent (79-30%) HP:0000708
8 hypothyroidism64 54 Occasional (29-5%) HP:0000821
9 precocious puberty64 54 Occasional (29-5%) HP:0000826
10 nevus flammeus64 54 Frequent (79-30%) HP:0001052
11 hypopigmented skin patches64 54 Frequent (79-30%) HP:0001053
12 intellectual disability64 54 Frequent (79-30%) HP:0001249
13 seizures64 54 Frequent (79-30%) HP:0001250
14 global developmental delay64 54 Frequent (79-30%) HP:0001263
15 abnormality of the liver64 54 Occasional (29-5%) HP:0001392
16 congestive heart failure64 54 Occasional (29-5%) HP:0001635
17 abnormality of the pancreas54 Occasional (29-5%)
18 abnormality of the respiratory system64 54 Occasional (29-5%) HP:0002086
19 respiratory insufficiency64 54 Occasional (29-5%) HP:0002093
20 emphysema64 54 Occasional (29-5%) HP:0002097
21 abnormality of the pleura54 Occasional (29-5%)
22 pneumothorax64 54 Occasional (29-5%) HP:0002107
23 eeg abnormality64 54 Very frequent (99-80%) HP:0002353
24 cerebral calcification64 54 Occasional (29-5%) HP:0002514
25 increased intracranial pressure64 54 Occasional (29-5%) HP:0002516
26 cortical dysplasia64 54 Frequent (79-30%) HP:0002539
27 aneurysm64 54 Occasional (29-5%) HP:0002617
28 neoplasm of the pancreas64 54 Occasional (29-5%) HP:0002894
29 macrodactyly64 54 Occasional (29-5%) HP:0004099
30 multiple renal cysts64 54 Occasional (29-5%) HP:0005562
31 renal angiomyolipoma64 54 Occasional (29-5%) HP:0006772
32 aplasia/hypoplasia of the corpus callosum64 54 Occasional (29-5%) HP:0007370
33 confetti-like hypopigmented macules64 54 Frequent (79-30%) HP:0007449
34 multiple cafe-au-lait spots64 54 Frequent (79-30%) HP:0007565
35 retinal hamartoma64 54 Frequent (79-30%) HP:0009594
36 subependymal nodules64 54 Very frequent (99-80%) HP:0009716
37 subependymal giant-cell astrocytoma64 54 Very frequent (99-80%) HP:0009718
38 shagreen patch64 54 Frequent (79-30%) HP:0009721
39 dental enamel pits64 54 Occasional (29-5%) HP:0009722
40 achromatic retinal patches64 54 Frequent (79-30%) HP:0009727
41 cardiac rhabdomyoma64 54 Occasional (29-5%) HP:0009729
42 chylothorax64 54 Occasional (29-5%) HP:0010310
43 skin tags64 54 Very frequent (99-80%) HP:0010609
44 angiofibromas64 54 Very frequent (99-80%) HP:0010615
45 arrhythmia64 54 Occasional (29-5%) HP:0011675
46 pulmonary lymphangiomyomatosis64 54 Occasional (29-5%) HP:0012798
47 ungual fibroma64 54 Very frequent (99-80%) HP:0100804
48 papule64 54 Very frequent (99-80%) HP:0200034
49 renal cyst64 HP:0000107
50 autism64 HP:0000717
51 cafe-au-lait spot64 HP:0000957
52 specific learning disability64 HP:0001328
53 subcutaneous nodule64 HP:0001482
54 wolff-parkinson-white syndrome64 HP:0001716
55 ependymoma64 HP:0002888
56 renal cell carcinoma64 HP:0005584
57 attention deficit hyperactivity disorder64 HP:0007018
58 projection of scalp hair onto lateral cheek64 HP:0009554
59 astrocytoma64 HP:0009592
60 cortical tubers64 HP:0009717
61 hypomelanotic macule64 HP:0009719
62 adenoma sebaceum64 HP:0009720
63 subungual fibromas64 HP:0009724
64 optic glioma64 HP:0009734
65 chordoma64 HP:0010762
66 infantile spasms64 HP:0012469
67 premature chromatid separation64 HP:0200024

UMLS symptoms related to Tuberous Sclerosis-1:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Tuberous Sclerosis-1 according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00112-A-010.8NF1, PTEN
2GR00293-A10.0MTOR, RPS6KB1
3GR00055-A-39.7MTOR, NF1, PKD1, RPS6KA1
4GR00055-A-19.5MTOR, NF1, PKD1, RPS6KA1, TSC1
5GR00366-A-1928.8DBH, MTOR, PTEN, RHEB, TSC1
6GR00381-A-18.6CDKN1B, MTOR, NF1, RHEB, RPS6KA1, RPS6KB1

MGI Mouse Phenotypes related to Tuberous Sclerosis-1 according to GeneCards Suite gene sharing:

41 (show all 17)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020069.0CDKN1B, NF1, PKD1, PTEN, RPS6KB1, TSC1
2MP:00053708.8CDKN1B, NF1, PKD1, PKHD1, PTEN, TSC1
3MP:00107718.7CDKN1B, COL5A1, DBH, NF1, PKD1, PTEN
4MP:00053888.6CDKN1B, MTOR, NF1, PKD1, PKHD1, PTEN
5MP:00053678.6CDKN1B, MTOR, NF1, PKD1, PKHD1, PTEN
6MP:00053758.4CDKN1B, DBH, EIF4EBP1, MTOR, PKD1, PTEN
7MP:00053807.9COL5A1, MTOR, NF1, PKD1, PTEN, RHEB
8MP:00053867.7CDKN1B, DBH, DCX, GFAP, MTOR, NF1
9MP:00053797.7CDKN1B, DBH, MTOR, NF1, PKD1, PKHD1
10MP:00028737.2COL5A1, DBH, GFAP, MTOR, NF1, PKD1
11MP:00053696.6CDKN1B, EIF4EBP1, GFAP, MTOR, NF1, PKD1
12MP:00053766.3CDKN1B, DBH, EIF4EBP1, GFAP, MTOR, NF1
13MP:00036316.1CDKN1B, DBH, DCX, GFAP, MTOR, NF1
14MP:00053845.8CDKN1B, EIF4EBP1, GFAP, MTOR, NF1, PKD1
15MP:00053855.3CDKN1B, COL5A1, DBH, EIF4EBP1, GFAP, MTOR
16MP:00053785.3CDKN1B, COL5A1, DBH, DCX, EIF4EBP1, GFAP
17MP:00107685.0CDKN1B, COL5A1, DBH, DCX, EIF4EBP1, GFAP

Drugs & Therapeutics for Tuberous Sclerosis-1

About this section

Drugs for Tuberous Sclerosis-1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 106)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Sirolimusapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
2
EverolimusapprovedPhase 4, Phase 2, Phase 3, Phase 11940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
3
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 3, Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
4
Doxycyclineapproved, investigational, vet_approvedPhase 4243564-25-054671203
Synonyms:
(2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10597-92-9
17086-28-1 (mono-hydrate)
2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)
24390-14-5
41411-66-9 (6-epimer, mono-hydrochloride)
5-Hydroxy-alpha-6-deoxytetracycline
5-hydroxy-α-6-deoxytetracycline
564-25-0
6-Deoxyoxytetracycline
6-Deoxytetracycline
6-alpha-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
69935-17-7 (mono-hydrochloride, di-hydrate)
6alpha-Deoxy-5-oxytetracycline
6alpha-deoxy-5-oxytetracycline
6α-deoxy-5-oxytetracycline
7164-70-7
7264-10-0
94088-85-4 (calcium salt (1:2))
AB08 (*Fosfatex)
AC1NQXW7
AC1NS4CW
AC1NUYS8
AC1O8PYM
Alti-Doxycycline
Anhydrous doxycycline
Apo-Doxy
Atridox
Azudoxat
BCBcMAP01_000024
BIDD:GT0146
BMY-28689
BPBio1_000951
BSPBio_000863
BSPBio_001936
BU-3839T
C06973
CHEBI:50845
CHEMBL1433
CID5281011
CID5353597
CID5463943
CID6713981
CPD001550033
D07876
DB00254
DMSC (*Fosfatex)
DOXCYCLINE ANHYDROUS
DOXY
DOXYCYCLINE CALCIUM
DOXYCYCLINE MONOHYDRATE
Deoxymykoin
DivK1c_000345
Dossiciclina
Dossiciclina [DCIT]
Doxcycline anhydrous
Doxiciclina
Doxiciclina [INN-Spanish]
Doxiciclina [Italian]
Doxitard
Doxivetin
Doxy-Caps
Doxy-Puren
Doxy-Tabs
Doxycen
Doxychel
Doxychel (TN)
Doxycin
Doxycyclin
Doxycycline (200mg/day) or Placebo
 
Doxycycline (INN)
Doxycycline (TN)
Doxycycline (anhydrous)
Doxycycline (internal use)
Doxycycline Hyclate
Doxycycline Monohydrate
Doxycycline anhydrous
Doxycycline hyclate
Doxycycline-Chinoin
Doxycyclinum
Doxycyclinum [INN-Latin]
Doxysol
Doxytec
Doxytetracycline
EINECS 209-271-1
GS-3065 (*monohydrate)
HMS2090E06
HSDB 3071
Hydramycin
IDI1_000345
Investin
Jenacyclin
KBio1_000345
KBio2_001287
KBio2_003855
KBio2_006423
KBio3_001156
KBioGR_001133
KBioSS_001287
LS-187766
LS-93868
Liviatin
Lopac0_000405
MolPort-002-507-423
Monodox
Monodox (*monohydrate)
NCGC00161602-01
NCGC00161602-03
NCGC00161602-04
NCGC00167961-01
NCGC00179395-01
NINDS_000345
NSC633557
Novo-Doxylin
Nu-Doxycycline
Oracea
Prestwick0_000852
Prestwick1_000852
Prestwick2_000852
Prestwick3_000852
Ronaxan
SAM002589932
SMP1_000107
SPBio_000246
SPBio_002784
STOCK1N-34341
Spanor
Spectrum2_000143
Spectrum3_000408
Spectrum4_000527
Spectrum5_000947
Spectrum_000807
Supracyclin
UNII-334895S862
UPCMLD-DP021
UPCMLD-DP021:001
Vibra-tabs
Vibramycin
Vibramycin (*monohydrate)
Vibramycin Novum
Vibramycine
Vibravenos
Vivox (*Hyclate)
alpha-6-Deoxy-5-hydroxytetracycline
alpha-6-Deoxyoxytetracycline
alpha-Doxycycline
doxycycline
5
VigabatrinapprovedPhase 4, Phase 22168506-86-5, 60643-86-95665
Synonyms:
( inverted question mark)-gamma-Vinyl GABA
(?)-gamma-Vinyl GABA
(R,S)-4-Amino-5-hexenoic acid
.gamma.-Vinyl-.gamma.-aminobutyric acid
.gamma.-Vinyl-GABA
4-Amino-5-hexenoic acid
4-Aminohexenoic acid
4-aminohex-5-enoic acid
60643-86-9
74046-07-4
AB00053309
AC1L1KUZ
Acid, gamma-Vinyl-gamma-Aminobutyric
Aventis Brand of Vigabatrin
BPBio1_000465
BPBio1_000925
BSPBio_000421
BSPBio_003469
Biomol-NT_000247
C07500
C6H11NO2
CHEBI:241484
CHEMBL89598
CID5665
CPP-109
D00535
D020888
DB01080
DivK1c_006760
EU-0101277
GVG
Gamma vinyl GABA
HMS1569F03
HMS2094M21
Hexenoic acid, 4-amino
Hoechst Brand of Vigabatrin
KBio1_001704
KBio2_000848
KBio2_003416
KBio2_005984
KBio3_002973
KBioSS_000848
LS-75569
Lopac0_001277
M071754
MDL 71,754
MDL 71754
 
MDL-71754
MolPort-003-666-796
NCGC00016087-03
NCGC00016087-08
NCGC00024802-02
NCGC00024802-03
NCGC00024802-04
NCGC00024802-05
NCGC00024802-06
Prestwick0_000501
Prestwick1_000501
Prestwick2_000501
Prestwick3_000501
Prestwick_837
RMI 71754
RMI-71754
RMI-71890
SPBio_002342
SPECTRUM1502036
Sabril
Sabril (TN)
Sabrilex
SpecPlus_000664
Spectrum3_001825
Spectrum_000368
V 8261
V8261_SIGMA
Vigabatrin
Vigabatrin (JAN/USAN/INN)
Vigabatrin Aventis Brand
Vigabatrin Hoechst Brand
Vigabatrin Yamanouchi Brand
Vigabatrin [USAN:BAN:INN]
Vigabatrin [USAN:INN:BAN]
Vigabatrina
Vigabatrina [Spanish]
Vigabatrine
Vigabatrine [French]
Vigabatrinum
Vigabatrinum [Latin]
Vinyl gamma-aminobutyric acid
Yamanouchi Brand of Vigabatrin
gamma Vinyl GABA
gamma Vinyl gamma Aminobutyric Acid
gamma-Vinyl GABA
gamma-Vinyl-GABA
gamma-Vinyl-gamma-Aminobutyric Acid
gamma-Vinyl-gamma-aminobutyric acid
vigabatrin
6Anti-Bacterial AgentsPhase 4, Phase 2, Phase 3, Phase 111226
7Anti-Infective AgentsPhase 4, Phase 2, Phase 3, Phase 122062
8Neurotransmitter AgentsPhase 4, Phase 218340
9Antifungal AgentsPhase 4, Phase 2, Phase 3, Phase 13696
10Immunosuppressive AgentsPhase 4, Phase 2, Phase 3, Phase 113086
11Antibiotics, AntitubercularPhase 4, Phase 2, Phase 3, Phase 17180
12AntimalarialsPhase 41246
13Antiparasitic AgentsPhase 42199
14Antiprotozoal AgentsPhase 42051
15AnticonvulsantsPhase 4, Phase 22695
16GABA AgentsPhase 4, Phase 21684
17
Methylprednisoloneapproved, vet_approvedPhase 3119383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
18
Prednisoloneapproved, vet_approvedPhase 3119350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
19
EthanolapprovedPhase 3213764-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
20
Calcitriolapproved, nutraceuticalPhase 321032222-06-3134070, 5280453
Synonyms:
(1R,3S)-5-{2-[(1R,3aS,7aR)-1-((R)-5-Hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol
(1alpha,3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trienetriol
(5Z,7E)-(1S,3R)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1-alpha,3-beta,25-triol
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta,25-triol
1 alpha,25-Dihydroxyvitamin D3
1,25 (OH)2 D3
1,25 Dihydroxycholecalciferol
1,25(OH)2-20epi-D3
1,25(OH)2D3 & CD4
1,25(OH2)D3
1,25-(OH)2-D3
1,25-(OH)2D3
1,25-DHCC
1,25-DIHYDROXYCHOLECALCIFEROL
1,25-Dihydroxycholecalciferol
1,25-Dihydroxycholecaliferol
1,25-Dihydroxyvitamin D
1,25-Dihydroxyvitamin D3
1,25-dihydroxy vitamin D3
1,25-dihydroxy-20-epi-Vitamin D3
1,25-dihydroxycholecalciferol
1,25D3
1-alpha,-1,25-Dihydroxyvitamin D3
1-alpha,25-Dihydroxycholecalciferol
1-alpha,25-Dihydroxyvitamin D3
1-alpha-25-Dihydroxyvitamin D3
1-alpha-25-dihydroxyvitamin D3
1.Alpha.,25-Dihydroxy-26,27-hexadeuterovitamin D3
17936_FLUKA
17936_SIGMA
1a,25-(OH)2D3
1a,25-Dihydroxycholecalciferol
1a,25-Dihydroxyvitamin D3
1alpha,25(OH)2-D3
1alpha,25(OH)2D3
1alpha,25-Dihydroxycholecalciferol
1alpha,25-Dihydroxyvitamin D
1alpha,25-Dihydroxyvitamin D3
1db1
1α,25(OH)2D3
1α,25-dihydroxycholecalciferol
1α,25-dihydroxyvitamin D3
20-epi-1alpha,25-dihydroxycholecaliferol
25-Dihydroxycholecalciferol
32222-06-3
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha,3beta,25-triol
9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta,.5Z,7E)- & CD4
9,10-seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha, 3beta, 25-triol
AC-1859
AC1NQX1S
Ambap32222-06-3
 
Asentar
BCBcMAP01_000160
BML2-E03
BSPBio_001287
C01673
CCRIS 5522
CD-2027
CHEBI:17823
CHEMBL846
CID5280453
CPD000466393
Calcijex
Calcijex, Silkis, Rocaltrol, Topitriol, Cholecalciferol,Calcitriol
Calcitriol
Calcitriol (JAN/USAN/INN)
Calcitriol [USAN:INN:BAN:JAN]
Calcitriolum
Calcitriolum [INN-Latin]
D00129
D1530_SIGMA
DN 101
DN-101
Decostriol
Dihydroxyvitamin D3
EINECS 250-963-8
HMS1361A09
HMS1791A09
HMS1989A09
HMS2051F06
HMS2089N03
HSDB 3482
IDI1_033757
LMST03020258
LS-53093
MC-1288
MC1288
MLS000759536
MLS001424122
MolPort-002-045-698
NCGC00161327-01
NCGC00161327-04
Ro 21-5535
Ro 215535
Ro-21-5535
Rocaltrol
Rocaltrol (TN)
S1466_Selleck
SAM001246772
SMR000466393
Silkis
Soltriol
Spectrum5_002061
Topitriol
Toptriol
U 49562
Vectical
ZINC03924790
calcitriol
vit D
21
Melatoninapproved, nutraceutical, vet_approvedPhase 3, Phase 126873-31-4896
Synonyms:
0E2B08C1-B325-45B1-8939-6F9081EFDFA4
4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID
5-22-12-00042 (Beilstein Handbook Reference)
5-Methoxy-N-acetyltryptamine
5-methoxy-N-acetyltryptamine
73-31-4
A4039/0172195
AB00053279
AC1L1A9Q
AC1Q4F1W
AC1Q4F1X
AKOS000276269
Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)- (9CI)
Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI)
Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]- (6CI,8CI)
Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}
Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}
BAS 01281092
BIDD:ER0618
BPBio1_000590
BRD-K97530723-001-07-6
BRN 0205542
BSPBio_000536
BSPBio_003006
Bio-0635
C01598
CAS-73-31-4
CCRIS 3472
CHEBI:16796
CHEMBL45
CID896
ChemDiv2_003916
Circadin
D008550
D08170
DB01065
DB08189
DivK1c_000353
EINECS 200-797-7
EU-0100787
HMS1380B22
HMS1569K18
HMS1921E04
HMS2089F09
HMS501B15
HSCI1_000400
HSDB 7509
I05-0076
I10-0345
IDI1_000353
IDI1_002631
IN1244
KBio1_000353
KBio2_000665
KBio2_003233
KBio2_005801
KBio3_002226
KBioGR_000591
KBioSS_000665
L001261
LS-1623
Lopac-M-5250
Lopac0_000787
M 5250
M-1200
M-1250
M1105
M5250_SIGMA
ML1
MLS000859594
MLS001055382
MLS001240204
MT6
Mela-T
Melapure
Melatol
Melatonex
Melatonex, Melatonin
Melatonin
Melatonin (synth.) standard-grade
 
Melatonin (synth.) ultra-pure
Melatonina
Melatonina (TN)
Melatonine
Melovine
MolPort-000-737-883
N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)-Acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide
N-Acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxy-tryptamine Melatonine
N-Acetyl-5-methoxytryptamine
N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-methoxyindol-3-yl)ethyl]acetamide
N-acetyl-5-methoxy-tryptamine
NCGC00015680-01
NCGC00015680-02
NCGC00015680-03
NCGC00015680-06
NCGC00015680-13
NCGC00090727-01
NCGC00090727-02
NCGC00090727-03
NCGC00090727-04
NCGC00090727-05
NCGC00090727-06
NCGC00090727-07
NCGC00090727-08
NCGC00090727-09
NCI60_004378
NINDS_000353
NMR/14327425
NSC 113928
NSC113928
NSC56423
Nature'S Harmony
Night Rest
Oprea1_104553
Oprea1_814234
PREVENTION 1 (MELATONIN) (PREVENTION 1)
PREVENTION 2 (MELATONIN)
PREVENTION 3 (MELATONIN)
PREVENTION 4 (MELATONIN)
PREVENTION 5 (MELATONIN)
Pineal Hormone
Posidorm
Prestwick0_000458
Prestwick1_000458
Prestwick2_000458
Prestwick3_000458
Prestwick_312
Regulin
Revital Melatonin
Rx Balance
S1204_Selleck
SDCCGMLS-0065812.P001
SDCCGMLS-0065812.P002
SMP2_000309
SMR000326666
SPBio_001527
SPBio_002475
SPECTRUM1500690
STK386880
Sleep Right
Spectrum2_001344
Spectrum3_001393
Spectrum4_000066
Spectrum5_001745
Spectrum_000185
TNP00300
UNII-JL5DK93RCL
Vivitas
WLN: T56 BMJ D2MV1 GO1
ZINC00057060
{N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} Acetamide
{N-[2-(5-methoxyindol-3-yl)ethyl]-} Acetamide
22Peripheral Nervous System AgentsPhase 323689
23Protective AgentsPhase 3, Phase 17443
24Neuroprotective AgentsPhase 31716
25Prednisolone hemisuccinatePhase 31193
26Prednisolone acetatePhase 31193
27Prednisolone phosphatePhase 31193
28Gastrointestinal AgentsPhase 3, Phase 28402
29Autonomic AgentsPhase 310150
30Methylprednisolone HemisuccinatePhase 31193
31AntiemeticsPhase 34022
32glucocorticoidsPhase 35103
33Anti-Inflammatory AgentsPhase 310729
34HormonesPhase 3, Phase 214415
35Hormone AntagonistsPhase 3, Phase 213180
36Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 213168
37Methylprednisolone acetatePhase 31193
38Pharmaceutical SolutionsPhase 3, Phase 28192
39Central Nervous System DepressantsPhase 3, Phase 113403
40VitaminsPhase 35282
41AntioxidantsPhase 3, Phase 13050
42Vasoconstrictor AgentsPhase 32122
43Bone Density Conservation AgentsPhase 33376
44MicronutrientsPhase 36001
45Calcium, DietaryPhase 35713
46Trace ElementsPhase 36001
47StrawberryNutraceuticalPhase 383
48
Propranololapproved, investigationalPhase 2228525-66-64946
Synonyms:
(+-)-Propranolol
(1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol
(R)-(+)-propranolol
(S)-(-)-PROPRANOLOL
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane
1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol
1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol
1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol
1-Isopropylamino-3-(1-naphthyloxy)-2-propanol
1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
13013-17-7
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9CI)
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)- (9CI)
3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol
4199-09-1
4199-10-4
525-66-6
AB00053537
AC1L1JA4
AC1Q1QBV
AC1Q1QC0
AKOS000588816
AY 64043
AY-20694
Anaprilin
Anapriline
Angilol
Apsolol
Avlocardyl
BPBio1_001040
BRD-A10070317-003-06-9
BSPBio_000944
BSPBio_002682
Bedranol
Beprane
Berkolol
Beta Neg
Beta-Neg
Beta-Propranolol
Beta-Tablinen
Beta-Timelets
Betachron
Betadren
Betalong
Bio-0732
Bio1_000367
Bio1_000856
Bio1_001345
C07407
C16H21NO2
CBDivE_006180
CCRIS 3082
CHEBI:8499
CHEMBL27
CID4946
Cardinol
Caridolol
Corpendol
D,L-Propranolol
D08443
DB00571
DL-Propranolol hydrochloride
Deralin
DivK1c_000023
Dl-Propranolol Hydrochloride
Dociton
Duranol
EINECS 208-378-0
EINECS 235-867-6
Efektolol
Elbrol
Etalong
Euprovasin
Frekven
HMS2090L21
Herzbase
ICI 45520
IDI1_000023
INDERIDE-40/25
INDERIDE-80/25
Ikopal
Inderal
Inderal La
Inderal hydrochloride
Inderalici
Inderex
Inderide
Inderol
Indobloc
InnoPranXL
 
Innopran XL
Intermigran
KBio1_000023
KBio2_002515
KBio2_005083
KBio2_007651
KBio3_001766
KBio3_001902
KBio3_002993
KBioGR_001347
KBioGR_001684
KBioGR_002515
KBioSS_002523
Kemi
Kemi S
L000679
LS-122410
LS-184129
Lopac0_000896
Migrastat
MolPort-001-794-623
NCGC00015798-07
NCGC00024690-02
NCGC00024690-03
NINDS_000023
NSC91523
Naprilin
Obsidan
Obzidan
Oposim
Oprea1_304193
PDSP1_000767
PDSP1_001607
PDSP1_001608
PDSP2_000755
PDSP2_001591
PDSP2_001592
Prano-Puren
Pranolol
Prestwick0_000952
Prestwick1_000952
Prestwick2_000952
Prestwick3_000952
Pronovan
Propanalol
Propanix
Propanolol
Propanolol [INN-Spanish]
Prophylux
Propranalol
Propranolol
Propranolol (INN)
Propranolol (TN)
Propranolol Hcl
Propranolol Hcl Intensol
Propranolol Hydrochloride
Propranolol [INN:BAN]
Propranololo
Propranololo [DCIT]
Propranololum
Propranololum [INN-Latin]
Propranur
Proprasylyt
Pylapron
R,S-Propranolol Hydrochloride
Racemic propranolol
Rapynogen
Reducor
Reducor Line
Reducor line
SPBio_001361
SPBio_001658
SPBio_003093
STK735510
Sagittol
Sawatal
Servanolol
Sloprolol
Spectrum2_001301
Spectrum2_001699
Spectrum3_000883
Spectrum3_001071
Spectrum4_000974
Spectrum4_001222
Spectrum5_000751
Sumial
Tesnol
UNII-9Y8NXQ24VQ
b-Propranolol
beta-Propranolol
cMAP_000071
etalong
propranolol
propranololo
β-Propranolol
49
MetforminapprovedPhase 21803657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
50
Octreotideapproved, investigationalPhase 222383150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate

Interventional clinical trials:

(show top 50)    (show all 69)
idNameStatusNCT IDPhase
1Rapamycin In Angiomyolipomas In Patients With Tuberous SclerosisCompletedNCT01217125Phase 4
2Doxycycline In Lymphangioleiomyomatosis (LAM)CompletedNCT00989742Phase 4
3Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301Active, not recruitingNCT02338609Phase 4
4Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) PatientsTerminatedNCT01266291Phase 4
5Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis ComplexUnknown statusNCT01730209Phase 2, Phase 3
6Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous MethylprednisoloneUnknown statusNCT00004645Phase 3
7Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)CompletedNCT00789828Phase 3
8Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00790400Phase 3
9Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)CompletedNCT02635789Phase 3
10Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous SclerosisCompletedNCT03140449Phase 3
11A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)RecruitingNCT02544763Phase 3
12A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset SeizuresActive, not recruitingNCT01713946Phase 3
13Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment DisabilitiesActive, not recruitingNCT01906866Phase 3
14An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)Enrolling by invitationNCT02544750Phase 3
15Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis ComplexNot yet recruitingNCT02634931Phase 3
16Topical Everolimus in Patients With Tuberous Sclerosis ComplexNot yet recruitingNCT02860494Phase 2, Phase 3
17Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentNot yet recruitingNCT02962414Phase 3
18Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockersUnknown statusNCT02104011Phase 2
19Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAMUnknown statusNCT00490789Phase 2
20Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial CancerUnknown statusNCT02188550Phase 2
21Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETsUnknown statusNCT02294006Phase 2
22Sirolimus in Treating Patients With Angiomyolipoma of the KidneyUnknown statusNCT00126672Phase 2
23Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAMCompletedNCT00457808Phase 2
24Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)CompletedNCT01289912Phase 2
25Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis ComplexCompletedNCT00411619Phase 1, Phase 2
26Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)CompletedNCT01070316Phase 1, Phase 2
27Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00792766Phase 1, Phase 2
28RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAMCompletedNCT00457964Phase 1, Phase 2
29Topical Rapamycin to Erase Angiofibromas in TSCCompletedNCT01526356Phase 2
30Rapalogues for Autism Phenotype in TSC: A Feasibility StudyCompletedNCT01929642Phase 2
31A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous SclerosisRecruitingNCT01954693Phase 2
32Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis ComplexRecruitingNCT02849457Phase 2
33Safety of Simvastatin in LAM and TSCRecruitingNCT02061397Phase 1, Phase 2
34A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCDRecruitingNCT02451696Phase 2
35Everolimus for Cancer With TSC1 or TSC2 MutationRecruitingNCT02201212Phase 2
36Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 MutationsRecruitingNCT03047213Phase 2
37Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 MutationsRecruitingNCT02352844Phase 2
38OLAParib COmbinationsRecruitingNCT02576444Phase 2
39NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple MyelomaRecruitingNCT02465060Phase 2
40Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific TreatmentRecruitingNCT02029001Phase 2
41Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line ChemotherapyActive, not recruitingNCT03082833Phase 2
42Phase II Trial of Vistusertib(AZD2014) Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard ChemotherapyNot yet recruitingNCT03166176Phase 2
43Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or LymphomasNot yet recruitingNCT03155620Phase 2
44A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComaWithdrawnNCT01690871Phase 2
45Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)CompletedNCT01031901Phase 1
46Tuberous Sclerosis Complex: Facial Angiofibroma Skin CreamCompletedNCT01853423Phase 1
47Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep DisturbancesCompletedNCT01903681Phase 1
48A Phase I Study of BKM120 and Everolimus in Advanced Solid MalignanciesActive, not recruitingNCT01470209Phase 1
49The Cognitive Variability in NF1 and TSC Monozygotic TwinsUnknown statusNCT02436746
50Tuberous Sclerosis Complex Natural History Study: Renal ManifestationsCompletedNCT00598455

Search NIH Clinical Center for Tuberous Sclerosis-1

Genetic Tests for Tuberous Sclerosis-1

About this section

Genetic tests related to Tuberous Sclerosis-1:

id Genetic test Affiliating Genes
1 Tuberous Sclerosis 127 24 TSC1
2 Tuberous Sclerosis Complex24 TSC2

Anatomical Context for Tuberous Sclerosis-1

About this section

MalaCards organs/tissues related to Tuberous Sclerosis-1:

36
Skin, Kidney, Brain, Heart, Lung, Pancreas, Liver

Publications for Tuberous Sclerosis-1

About this section

Articles related to Tuberous Sclerosis-1:

idTitleAuthorsYear
1
The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. (11175345)
2000

Variations for Tuberous Sclerosis-1

About this section

UniProtKB/Swiss-Prot genetic disease variations for Tuberous Sclerosis-1:

70
id Symbol AA change Variation ID SNP ID
1TSC1p.Leu191HisVAR_009399rs118203403
2TSC1p.Met224ArgVAR_009401rs118203426
3TSC1p.Gln654GluVAR_009407rs75820036
4TSC1p.Ala726GluVAR_009408rs118203655
5TSC1p.Thr899SerVAR_009412rs76801599
6TSC1p.Leu72ProVAR_054387rs118203354
7TSC1p.Arg500GlnVAR_054391rs118203538
8TSC1p.Leu117ProVAR_070637rs118203368
9TSC1p.Leu180ProVAR_070643rs118203396

Clinvar genetic disease variations for Tuberous Sclerosis-1:

5 (show all 177)
id Gene Variation Type Significance SNP ID Assembly Location
1TSC2NM_ 000548.4(TSC2): c.4642delC (p.Leu1548Cysfs)deletionPathogenicrs137854083GRCh37Chr 16, 2135303: 2135303
2TSC2NM_ 000548.4(TSC2): c.5024C> T (p.Pro1675Leu)SNVPathogenicrs45483392GRCh37Chr 16, 2137898: 2137898
3TSC2NM_ 000548.4(TSC2): c.34A> T (p.Lys12Ter)SNVPathogenicrs45512692GRCh37Chr 16, 2098650: 2098650
4TSC2NM_ 000548.4(TSC2): c.2056_ 2059dupTACT (p.Ser687Leufs)duplicationPathogenicrs137854337GRCh37Chr 16, 2121894: 2121897
5TSC2NM_ 000548.4(TSC2): c.1513C> T (p.Arg505Ter)SNVPathogenicrs45517179GRCh37Chr 16, 2114342: 2114342
6TSC2NM_ 000548.4(TSC2): c.1832G> A (p.Arg611Gln)SNVPathogenicrs28934872GRCh37Chr 16, 2120572: 2120572
7TSC2NM_ 000548.4(TSC2): c.2150T> G (p.Leu717Arg)SNVPathogenicrs45517214GRCh37Chr 16, 2122294: 2122294
8TSC2NM_ 000548.4(TSC2): c.1432C> T (p.Gln478Ter)SNVPathogenicrs121964862GRCh37Chr 16, 2113043: 2113043
9TSC2NM_ 000548.4(TSC2): c.1096G> T (p.Glu366Ter)SNVPathogenicrs45517148GRCh37Chr 16, 2110791: 2110791
10TSC2NM_ 000548.4(TSC2): c.4508A> C (p.Gln1503Pro)SNVPathogenicrs45516293GRCh37Chr 16, 2134966: 2134966
11TSC2NM_ 000548.4(TSC2): c.5238_ 5255del18 (p.His1746_ Arg1751del)deletionPathogenicrs137854218GRCh37Chr 16, 2138305: 2138322
12TSC2NM_ 000548.4(TSC2): c.2714G> A (p.Arg905Gln)SNVPathogenicrs45517259GRCh37Chr 16, 2126143: 2126143
13TSC2NM_ 000548.4(TSC2): c.2713C> T (p.Arg905Trp)SNVPathogenicrs45517258GRCh37Chr 16, 2126142: 2126142
14TSC2NM_ 000548.4(TSC2): c.2713C> G (p.Arg905Gly)SNVPathogenicrs45517258GRCh37Chr 16, 2126142: 2126142
15TSC2NM_ 000548.4(TSC2): c.2355+2_ 2355+5delTAGGdeletionPathogenicrs137854250GRCh37Chr 16, 2122986: 2122989
16TSC2NM_ 000548.4(TSC2): c.1322G> A (p.Trp441Ter)SNVPathogenicrs45515894GRCh37Chr 16, 2112562: 2112562
17TSC1NM_ 000368.4(TSC1): c.2515_ 2518delGAGT (p.Glu839Argfs)deletionPathogenicrs794727320GRCh37Chr 9, 135776209: 135776212
18TSC1NM_ 000368.4(TSC1): c.2675_ 2676delGA (p.Arg892Lysfs)deletionPathogenicrs118203726GRCh38Chr 9, 132897560: 132897561
19TSC1NM_ 000368.4(TSC1): c.1530_ 1531delCA (p.Asp510Glufs)deletionPathogenicrs118203544GRCh37Chr 9, 135781434: 135781435
20TSC1NM_ 000368.4(TSC1): c.1998-1G> TSNVPathogenicrs118203614GRCh38Chr 9, 132904455: 132904455
21TSC1NM_ 001162426.1(TSC1): c.2266G> T (p.Glu756Ter)SNVLikely pathogenicrs1057519319GRCh38Chr 9, 132902727: 132902727
22TSC1NC_ 000009.12: g.(132875199_ 132878172)_ (132897610_ 132900715)deldeletionPathogenicGRCh38Chr 9, 132875199: 132900715
23TSC1NM_ 000368.4(TSC1): c.2341_ 2360dup20 (p.Glu787Aspfs)duplicationPathogenicGRCh38Chr 9, 132902636: 132902655
24TSC1NM_ 000368.4(TSC1): c.1518delC (p.Tyr508Thrfs)deletionPathogenicrs1060503210GRCh38Chr 9, 132906060: 132906060
25TSC1NM_ 000368.4(TSC1): c.2165delA (p.Lys722Argfs)deletionPathogenicrs1060503213GRCh38Chr 9, 132903694: 132903694
26TSC1NM_ 000368.4(TSC1): c.2391+1G> CSNVLikely pathogenicrs1060503224GRCh38Chr 9, 132902604: 132902604
27TSC1NM_ 000368.4(TSC1): c.1152delA (p.Gly385Glufs)deletionPathogenicrs118203501GRCh37Chr 9, 135786069: 135786069
28TSC1NM_ 000368.4(TSC1): c.1257delC (p.Arg420Glyfs)deletionPathogenicrs118203506GRCh37Chr 9, 135785964: 135785964
29TSC1NM_ 000368.4(TSC1): c.1431_ 1434delAGAA (p.Glu478Lysfs)deletionPathogenicrs118203527GRCh37Chr 9, 135782122: 135782125
30TSC1NM_ 000368.4(TSC1): c.1498C> T (p.Arg500Ter)SNVPathogenicrs118203537GRCh37Chr 9, 135781467: 135781467
31TSC1NM_ 000368.4(TSC1): c.1525C> T (p.Arg509Ter)SNVPathogenicrs118203542GRCh37Chr 9, 135781440: 135781440
32TSC1NM_ 000368.4(TSC1): c.1580_ 1581delAG (p.Gln527Argfs)deletionPathogenicrs118203550GRCh37Chr 9, 135781384: 135781385
33TSC1NM_ 000368.4(TSC1): c.1959dupA (p.Gln654Thrfs)duplicationPathogenicrs118203603GRCh37Chr 9, 135781006: 135781006
34TSC1NM_ 000368.4(TSC1): c.1963C> T (p.Gln655Ter)SNVPathogenicrs118203606GRCh37Chr 9, 135781002: 135781002
35TSC1NM_ 000368.4(TSC1): c.1997+1G> ASNVPathogenicrs118203610GRCh37Chr 9, 135780967: 135780967
36TSC1NM_ 000368.4(TSC1): c.2074C> T (p.Arg692Ter)SNVPathogenicrs118203631GRCh37Chr 9, 135779172: 135779172
37TSC1NM_ 000368.4(TSC1): c.211-2A> CSNVPathogenicrs118203352GRCh37Chr 9, 135801128: 135801128
38TSC1NM_ 000368.4(TSC1): c.2111_ 2112delAT (p.Tyr704Terfs)deletionPathogenicrs118203645GRCh37Chr 9, 135779134: 135779135
39TSC1NM_ 000368.4(TSC1): c.2227C> T (p.Gln743Ter)SNVPathogenicrs118203661GRCh37Chr 9, 135778156: 135778156
40TSC1NM_ 000368.4(TSC1): c.2283C> A (p.Tyr761Ter)SNVPathogenicrs118203668GRCh37Chr 9, 135778100: 135778100
41TSC1NM_ 000368.4(TSC1): c.2341C> T (p.Gln781Ter)SNVPathogenicrs118203680GRCh37Chr 9, 135778042: 135778042
42TSC1NM_ 000368.4(TSC1): c.2356C> T (p.Arg786Ter)SNVPathogenicrs118203682GRCh37Chr 9, 135778027: 135778027
43TSC1NM_ 000368.4(TSC1): c.2401G> T (p.Glu801Ter)SNVPathogenicrs118203687GRCh37Chr 9, 135777077: 135777077
44TSC1NM_ 000368.3(TSC1): c.2509_ 2512delAACA (p.Asn837Valfs)deletionPathogenicrs118203707GRCh37Chr 9, 135776215: 135776218
45TSC1NM_ 000368.4(TSC1): c.2569delG (p.Glu857Argfs)deletionPathogenicrs118203712GRCh37Chr 9, 135776158: 135776158
46TSC1NM_ 000368.4(TSC1): c.2689C> T (p.Gln897Ter)SNVPathogenicrs118203727GRCh37Chr 9, 135772934: 135772934
47TSC1NM_ 000368.4(TSC1): c.271_ 272delTC (p.Ser91Valfs)deletionPathogenicrs118203360GRCh37Chr 9, 135801065: 135801066
48TSC1NM_ 000368.4(TSC1): c.395_ 406delGCGTCTTGGTGTinsCA (p.Gly132Alafs)indelPathogenicrs118203380GRCh37Chr 9, 135798837: 135798848
49TSC1NM_ 000368.4(TSC1): c.491G> A (p.Trp164Ter)SNVPathogenicrs118203387GRCh37Chr 9, 135798752: 135798752
50TSC1NM_ 000368.4(TSC1): c.569G> C (p.Arg190Pro)SNVLikely pathogenicrs118203402GRCh37Chr 9, 135797300: 135797300
51TSC1NM_ 000368.4(TSC1): c.664-1G> ASNVPathogenicrs118203423GRCh37Chr 9, 135796824: 135796824
52TSC1NM_ 000368.4(TSC1): c.664-1G> CSNVPathogenicrs118203423GRCh37Chr 9, 135796824: 135796824
53TSC1NM_ 000368.4(TSC1): c.682C> T (p.Arg228Ter)SNVPathogenicrs118203427GRCh37Chr 9, 135796805: 135796805
54TSC1NM_ 000368.4(TSC1): c.733C> T (p.Arg245Ter)SNVPathogenicrs118203434GRCh37Chr 9, 135796754: 135796754
55TSC1NM_ 000368.4(TSC1): c.737+1G> ASNVPathogenicrs118203438GRCh37Chr 9, 135796749: 135796749
56TSC1NM_ 000368.4(TSC1): c.737+3A> GSNVLikely pathogenicrs118203439GRCh37Chr 9, 135796747: 135796747
57TSC1NM_ 000368.4(TSC1): c.812_ 813delAT (p.Tyr271Terfs)deletionPathogenicrs118203451GRCh37Chr 9, 135787769: 135787770
58TSC1NM_ 000368.4(TSC1): c.901_ 902delCA (p.Gln301Glufs)deletionPathogenicrs118203464GRCh37Chr 9, 135787680: 135787681
59TSC1NM_ 000368.4(TSC1): c.973C> T (p.Gln325Ter)SNVPathogenicrs118203474GRCh37Chr 9, 135786896: 135786896
60TSC1NM_ 000368.4(TSC1): c.989_ 990delTG (p.Leu330Glnfs)deletionPathogenicrs118203479GRCh37Chr 9, 135786879: 135786880
61TSC1NM_ 000368.4(TSC1): c.989dupT (p.Ser331Glufs)duplicationPathogenicrs118203478GRCh37Chr 9, 135786880: 135786880
62TSC2NM_ 000548.4(TSC2): c.1085T> C (p.Leu362Pro)SNVLikely pathogenicrs137854345GRCh37Chr 16, 2110780: 2110780
63TSC2NM_ 000548.4(TSC2): c.133_ 136delCTGA (p.Leu45Glufs)deletionPathogenicrs137854360GRCh37Chr 16, 2098749: 2098752
64TSC2NM_ 000548.4(TSC2): c.1372C> T (p.Arg458Ter)SNVPathogenicrs45517169GRCh37Chr 16, 2112983: 2112983
65TSC2NM_ 000548.4(TSC2): c.226-2A> GSNVPathogenicrs45517096GRCh37Chr 16, 2103341: 2103341
66TSC2NM_ 000548.4(TSC2): c.2356-2A> CSNVPathogenicrs45517229GRCh37Chr 16, 2124199: 2124199
67TSC2NM_ 000548.4(TSC2): c.3094C> T (p.Arg1032Ter)SNVPathogenicrs45465195GRCh37Chr 16, 2129160: 2129160
68TSC2NM_ 000548.4(TSC2): c.3095G> C (p.Arg1032Pro)SNVLikely pathogenicrs45491698GRCh37Chr 16, 2129161: 2129161
69TSC2NM_ 000548.4(TSC2): c.3206_ 3207delTG (p.Val1069Aspfs)deletionPathogenicrs137854076GRCh37Chr 16, 2129351: 2129352
70TSC2NM_ 000548.4(TSC2): c.3412C> T (p.Arg1138Ter)SNVPathogenicrs45451497GRCh37Chr 16, 2130180: 2130180
71TSC2NM_ 000548.4(TSC2): c.352dupG (p.Val118Glyfs)duplicationPathogenicrs137853982GRCh37Chr 16, 2104312: 2104312
72TSC2NM_ 000548.4(TSC2): c.3532C> T (p.Gln1178Ter)SNVPathogenicrs45517297GRCh37Chr 16, 2130300: 2130300
73TSC2NM_ 000548.4(TSC2): c.4115_ 4116delTG (p.Val1372Glyfs)deletionPathogenicrs137854368GRCh37Chr 16, 2134338: 2134339
74TSC2NM_ 000548.4(TSC2): c.4207delG (p.Asp1403Thrfs)deletionPathogenicrs137854273GRCh37Chr 16, 2134430: 2134430
75TSC2NM_ 000548.4(TSC2): c.4544_ 4547delACAA (p.Asn1515Serfs)deletionPathogenicrs137854175GRCh37Chr 16, 2135002: 2135005
76TSC2NM_ 000548.4(TSC2): c.4573C> T (p.Gln1525Ter)SNVPathogenicrs45517352GRCh37Chr 16, 2135234: 2135234
77TSC2NM_ 000548.4(TSC2): c.4829G> A (p.Trp1610Ter)SNVPathogenicrs45517371GRCh37Chr 16, 2136360: 2136360
78TSC2NM_ 000548.4(TSC2): c.4842_ 4844delCAT (p.Ile1614del)deletionPathogenicrs137854331GRCh37Chr 16, 2136373: 2136375
79TSC2NM_ 000548.4(TSC2): c.4846C> T (p.Gln1616Ter)SNVPathogenicrs45455296GRCh37Chr 16, 2136377: 2136377
80TSC2NM_ 000548.4(TSC2): c.4952A> G (p.Asn1651Ser)SNVPathogenicrs45517382GRCh37Chr 16, 2136835: 2136835
81TSC2NM_ 000548.4(TSC2): c.4993C> T (p.Gln1665Ter)SNVPathogenicrs45448101GRCh37Chr 16, 2137867: 2137867
82TSC2NM_ 000548.4(TSC2): c.5110T> A (p.Ser1704Thr)SNVLikely pathogenicrs45474691GRCh37Chr 16, 2138090: 2138090
83TSC2NM_ 000548.4(TSC2): c.5150T> C (p.Leu1717Pro)SNVPathogenicrs45517398GRCh37Chr 16, 2138130: 2138130
84TSC2NM_ 000548.4(TSC2): c.5219G> A (p.Trp1740Ter)SNVPathogenicrs137854219GRCh37Chr 16, 2138286: 2138286
85TSC2NM_ 000548.4(TSC2): c.5252_ 5259+19del27deletionPathogenicrs137854397GRCh37Chr 16, 2138319: 2138345
86TSC2NM_ 000548.4(TSC2): c.5254C> T (p.Gln1752Ter)SNVPathogenicrs45517414GRCh37Chr 16, 2138321: 2138321
87TSC2NM_ 000548.4(TSC2): c.646G> T (p.Glu216Ter)SNVPathogenicrs45517118GRCh37Chr 16, 2106243: 2106243
88TSC2NM_ 000548.4(TSC2): c.849-1G> ASNVPathogenicrs45506396GRCh37Chr 16, 2108747: 2108747
89TSC2NM_ 000548.4(TSC2): c.976-15G> ASNVPathogenicrs45517150GRCh37Chr 16, 2110656: 2110656
90TSC2NM_ 000548.4(TSC2): c.648+1G> ASNVPathogenicrs45488893GRCh37Chr 16, 2106246: 2106246
91TSC2NM_ 000548.4(TSC2): c.5259+1delGdeletionPathogenicrs137854317GRCh37Chr 16, 2138327: 2138327
92TSC2NM_ 000548.4(TSC2): c.5160+1G> ASNVPathogenicrs45517399GRCh37Chr 16, 2138141: 2138141
93TSC2NM_ 000548.4(TSC2): c.5160+1G> TSNVPathogenicrs45517399GRCh37Chr 16, 2138141: 2138141
94TSC2NM_ 000548.4(TSC2): c.826_ 827delAT (p.Met276Valfs)deletionPathogenicrs137853977GRCh37Chr 16, 2107157: 2107158
95TSC2NM_ 000548.4(TSC2): c.4989+1G> ASNVPathogenicrs45517386GRCh37Chr 16, 2136873: 2136873
96TSC2NM_ 000548.4(TSC2): c.5227C> T (p.Arg1743Trp)SNVPathogenicrs45517412GRCh37Chr 16, 2138294: 2138294
97TSC2NM_ 000548.4(TSC2): c.4646A> G (p.Tyr1549Cys)SNVLikely pathogenicrs45517355GRCh37Chr 16, 2135307: 2135307
98TSC2NM_ 000548.4(TSC2): c.4318C> T (p.Gln1440Ter)SNVPathogenicrs45517337GRCh37Chr 16, 2134541: 2134541
99TSC2NM_ 000548.4(TSC2): c.3696dupT (p.Asn1233Terfs)duplicationPathogenicrs137854210GRCh37Chr 16, 2131681: 2131681
100TSC2NM_ 000548.4(TSC2): c.4096G> T (p.Glu1366Ter)SNVPathogenicrs45517327GRCh37Chr 16, 2134319: 2134319
101TSC2NM_ 000548.4(TSC2): c.2666C> T (p.Ala889Val)SNVPathogenicrs137854155GRCh37Chr 16, 2126095: 2126095
102TSC2NM_ 000548.4(TSC2): c.2459_ 2461delTCA (p.Ile820del)deletionLikely pathogenicrs137854128GRCh37Chr 16, 2124304: 2124306
103TSC2NM_ 000548.4(TSC2): c.2690T> C (p.Phe897Ser)SNVPathogenicrs45517255GRCh37Chr 16, 2126119: 2126119
104TSC2NM_ 000548.4(TSC2): c.1760_ 1761delAT (p.Tyr587Terfs)deletionPathogenicrs137854371GRCh37Chr 16, 2120500: 2120501
105TSC2NM_ 000548.4(TSC2): c.1444-2A> GSNVPathogenicrs45517174GRCh37Chr 16, 2114271: 2114271
106TSC2NM_ 000548.4(TSC2): c.1831C> T (p.Arg611Trp)SNVPathogenicrs45469298GRCh37Chr 16, 2120571: 2120571
107TSC2NM_ 000548.4(TSC2): c.1599+1G> ASNVPathogenicrs45517182GRCh37Chr 16, 2114429: 2114429
108TSC2NM_ 000548.4(TSC2): c.138_ 138+1delAGdeletionPathogenicrs137854117GRCh37Chr 16, 2098754: 2098755
109TSC2NM_ 000548.4(TSC2): c.2328C> A (p.Tyr776Ter)SNVPathogenicrs45517225GRCh37Chr 16, 2122957: 2122957
110TSC2NM_ 000548.4(TSC2): c.1229T> G (p.Leu410Arg)SNVLikely pathogenicrs137854298GRCh37Chr 16, 2111981: 2111981
111TSC2NM_ 000548.4(TSC2): c.2071delC (p.Arg691Alafs)deletionPathogenicrs137854071GRCh37Chr 16, 2121909: 2121909
112TSC2NM_ 000548.4(TSC2): c.2410T> C (p.Cys804Arg)SNVPathogenic/ Likely pathogenicrs137853995GRCh37Chr 16, 2124255: 2124255
113TSC2NM_ 000548.4(TSC2): c.2098-1G> ASNVPathogenicrs45517212GRCh37Chr 16, 2122241: 2122241
114TSC2NM_ 000548.4(TSC2): c.3098dupA (p.Tyr1033Terfs)duplicationPathogenicrs137854015GRCh37Chr 16, 2129164: 2129164
115TSC2NM_ 000548.4(TSC2): c.2108G> A (p.Trp703Ter)SNVPathogenicrs45517213GRCh37Chr 16, 2122252: 2122252
116TSC2NM_ 000548.4(TSC2): c.268C> T (p.Gln90Ter)SNVPathogenicrs45517099GRCh37Chr 16, 2103385: 2103385
117TSC2NM_ 000548.4(TSC2): c.2477T> C (p.Leu826Pro)SNVLikely pathogenicrs45517239GRCh37Chr 16, 2124322: 2124322
118TSC2NM_ 000548.4(TSC2): c.3598C> T (p.Arg1200Trp)SNVPathogenicrs45438205GRCh37Chr 16, 2130366: 2130366
119TSC2NM_ 000548.4(TSC2): c.2546-2A> GSNVPathogenicrs45517246GRCh37Chr 16, 2125798: 2125798
120TSC2NM_ 000548.4(TSC2): c.4223delG (p.Gly1408Alafs)deletionPathogenicrs137854427GRCh37Chr 16, 2134446: 2134446
121TSC2NM_ 000548.4(TSC2): c.496C> T (p.Gln166Ter)SNVPathogenicrs45517111GRCh37Chr 16, 2105417: 2105417
122TSC2NM_ 000548.4(TSC2): c.3395C> A (p.Ser1132Ter)SNVPathogenicrs137854074GRCh37Chr 16, 2129668: 2129668
123TSC2NM_ 000548.4(TSC2): c.2639+1G> CSNVPathogenicrs45517252GRCh37Chr 16, 2125894: 2125894
124TSC2NM_ 000548.4(TSC2): c.488_ 489delTT (p.Phe163Cysfs)deletionPathogenicrs137854122GRCh37Chr 16, 2105409: 2105410
125TSC2NM_ 000548.4(TSC2): c.4912_ 4914delAAG (p.Lys1638del)deletionPathogenicrs137854261GRCh37Chr 16, 2136795: 2136797
126TSC2NM_ 000548.4(TSC2): c.730T> C (p.Cys244Arg)SNVPathogenicrs137854101GRCh37Chr 16, 2106726: 2106726
127TSC2NM_ 000548.4(TSC2): c.4927A> C (p.Asn1643His)SNVPathogenicrs45517379GRCh37Chr 16, 2136810: 2136810
128TSC2NM_ 000548.4(TSC2): c.774+1G> ASNVPathogenicrs45517128GRCh37Chr 16, 2106771: 2106771
129TSC2NM_ 000548.4(TSC2): c.848+1G> ASNVPathogenicrs45466296GRCh37Chr 16, 2107180: 2107180
130TSC2NM_ 000548.4(TSC2): c.848+281C> TSNVPathogenicrs45517132GRCh37Chr 16, 2107460: 2107460
131TSC2NM_ 000548.4(TSC2): c.5138G> A (p.Arg1713His)SNVPathogenic/ Likely pathogenicrs45517395GRCh37Chr 16, 2138118: 2138118
132TSC2NM_ 000548.4(TSC2): c.5138G> C (p.Arg1713Pro)SNVLikely pathogenicrs45517395GRCh37Chr 16, 2138118: 2138118
133TSC2NM_ 000548.4(TSC2): c.5161-1G> ASNVPathogenicrs45517404GRCh37Chr 16, 2138227: 2138227
134TSC2NM_ 000548.4(TSC2): c.972C> A (p.Tyr324Ter)SNVPathogenicrs45517143GRCh37Chr 16, 2108871: 2108871
135TSC2NM_ 000548.4(TSC2): c.5170C> T (p.Gln1724Ter)SNVPathogenicrs45472701GRCh37Chr 16, 2138237: 2138237
136TSC2NM_ 000548.4(TSC2): c.5228G> A (p.Arg1743Gln)SNVPathogenicrs45507199GRCh37Chr 16, 2138295: 2138295
137TSC2NM_ 000548.4(TSC2): c.4934_ 4935delTT (p.Phe1645Cysfs)deletionPathogenicrs137854249GRCh37Chr 16, 2136817: 2136818
138TSC2NM_ 000548.4(TSC2): c.4375C> T (p.Arg1459Ter)SNVPathogenicrs45517340GRCh37Chr 16, 2134598: 2134598
139TSC2NM_ 000548.4(TSC2): c.4662+1G> ASNVPathogenicrs45514095GRCh37Chr 16, 2135324: 2135324
140TSC2NM_ 000548.4(TSC2): c.569dupA (p.Tyr190Terfs)duplicationPathogenicrs137854359GRCh37Chr 16, 2105490: 2105490
141TSC2NM_ 000548.4(TSC2): c.3106T> C (p.Ser1036Pro)SNVPathogenicrs45517281GRCh37Chr 16, 2129172: 2129172
142TSC2NM_ 000548.4(TSC2): c.4180_ 4181delCT (p.Leu1394Alafs)deletionPathogenicrs137854363GRCh37Chr 16, 2134403: 2134404
143TSC2NM_ 000548.4(TSC2): c.336+1G> ASNVPathogenicrs45517102GRCh37Chr 16, 2103454: 2103454
144TSC2NM_ 000548.4(TSC2): c.3397+5G> ASNVPathogenicrs45501492GRCh37Chr 16, 2129675: 2129675
145TSC2NM_ 000548.4(TSC2): c.3401delG (p.Gly1134Alafs)deletionPathogenicrs137854314GRCh37Chr 16, 2130169: 2130169
146TSC2NM_ 000548.4(TSC2): c.3442C> T (p.Gln1148Ter)SNVPathogenicrs45477491GRCh37Chr 16, 2130210: 2130210
147TSC2NM_ 000548.4(TSC2): c.4762C> T (p.Gln1588Ter)SNVPathogenicrs45479192GRCh37Chr 16, 2136293: 2136293
148TSC2NM_ 000548.4(TSC2): c.2194C> T (p.Gln732Ter)SNVPathogenicrs45517216GRCh37Chr 16, 2122338: 2122338
149TSC2NM_ 000548.4(TSC2): c.2251C> T (p.Arg751Ter)SNVPathogenicrs45517222GRCh37Chr 16, 2122880: 2122880
150TSC2NM_ 000548.4(TSC2): c.1563dupA (p.His522Thrfs)duplicationPathogenicrs137854023GRCh37Chr 16, 2114392: 2114392
151TSC2NM_ 000548.4(TSC2): c.3611G> A (p.Gly1204Glu)SNVLikely pathogenicrs45462194GRCh37Chr 16, 2131596: 2131596
152TSC2NM_ 000548.4(TSC2): c.1793A> G (p.Tyr598Cys)SNVLikely pathogenicrs45509791GRCh37Chr 16, 2120533: 2120533
153TSC2NM_ 000548.4(TSC2): c.1255C> T (p.Pro419Ser)SNVPathogenicrs45517159GRCh37Chr 16, 2112007: 2112007
154TSC2NM_ 000548.4(TSC2): c.1397T> G (p.Leu466Arg)SNVLikely pathogenicrs45481199GRCh37Chr 16, 2113008: 2113008
155TSC1NM_ 000368.4(TSC1): c.1888_ 1891delAAAG (p.Lys630Glnfs)deletionPathogenicrs118203595GRCh37Chr 9, 135781074: 135781077
156TSC1NM_ 000368.4(TSC1): c.749T> A (p.Leu250Ter)SNVPathogenicrs118203447GRCh37Chr 9, 135787833: 135787833
157TSC1NM_ 000368.4(TSC1): c.1904_ 1905delCA (p.Thr635Argfs)deletionPathogenicrs118203597GRCh37Chr 9, 135781060: 135781061
158TSC1NM_ 000368.4(TSC1): c.671T> G (p.Met224Arg)SNVPathogenicrs118203426GRCh37Chr 9, 135796816: 135796816
159TSC1NM_ 000368.4(TSC1): c.539T> C (p.Leu180Pro)SNVPathogenicrs118203396GRCh37Chr 9, 135797330: 135797330
160TSC1NM_ 000368.4(TSC1): c.260T> G (p.Leu87Ter)SNVPathogenicrs397514776GRCh37Chr 9, 135801077: 135801077
161TSC1NM_ 000368.4(TSC1): c.2272C> T (p.Gln758Ter)SNVPathogenicrs397514783GRCh37Chr 9, 135778111: 135778111
162TSC1NM_ 000368.4(TSC1): c.182T> G (p.Leu61Arg)SNVLikely pathogenicrs118203345GRCh37Chr 9, 135802616: 135802616
163TSC1NM_ 000368.4(TSC1): c.1680_ 1702del23 (p.Ser561Argfs)deletionPathogenicrs118203557GRCh37Chr 9, 135781263: 135781285
164TSC1NM_ 000368.4(TSC1): c.2041+1G> ASNVPathogenicrs397514842GRCh37Chr 9, 135779797: 135779797
165TSC1NM_ 000368.4(TSC1): c.2389C> T (p.Gln797Ter)SNVPathogenicrs397514862GRCh37Chr 9, 135777994: 135777994
166TSC1NM_ 000368.4(TSC1): c.866C> G (p.Ser289Ter)SNVPathogenicrs397514867GRCh37Chr 9, 135787716: 135787716
167TSC1NM_ 000368.4(TSC1): c.2698C> T (p.Gln900Ter)SNVPathogenicrs397514871GRCh37Chr 9, 135772925: 135772925
168TSC1NM_ 000368.4(TSC1): c.2672delA (p.Asn891Thrfs)deletionPathogenicrs397514875GRCh37Chr 9, 135772951: 135772951
169TSC2NM_ 000548.4(TSC2): c.1447G> T (p.Glu483Ter)SNVPathogenicrs397515297GRCh37Chr 16, 2114276: 2114276
170TSC2NM_ 000548.4(TSC2): c.2688G> A (p.Trp896Ter)SNVPathogenicrs397514913GRCh37Chr 16, 2126117: 2126117
171TSC2NM_ 000548.4(TSC2): c.3623G> A (p.Trp1208Ter)SNVPathogenicrs397514979GRCh37Chr 16, 2131608: 2131608
172TSC2NM_ 000548.4(TSC2): c.4147_ 4163dup17 (p.Pro1389Alafs)duplicationPathogenicrs397515009GRCh37Chr 16, 2134370: 2134386
173TSC2NM_ 000548.4(TSC2): c.3236C> A (p.Ser1079Ter)SNVPathogenicrs397515087GRCh37Chr 16, 2129381: 2129381
174TSC2NM_ 000548.4(TSC2): c.4316delG (p.Gly1439Alafs)deletionPathogenicrs397515200GRCh37Chr 16, 2134539: 2134539
175TSC2NM_ 000548.4(TSC2): c.4868C> T (p.Thr1623Ile)SNVLikely pathogenicrs397515220GRCh37Chr 16, 2136751: 2136751
176TSC2NM_ 000548.4(TSC2): c.1959_ 1960delAG (p.Gly654Leufs)deletionPathogenicrs397515226GRCh37Chr 16, 2121797: 2121798
177TSC2NM_ 000548.4(TSC2): c.1443+1G> TSNVPathogenicrs397515257GRCh37Chr 16, 2113055: 2113055

Expression for genes affiliated with Tuberous Sclerosis-1

About this section
Search GEO for disease gene expression data for Tuberous Sclerosis-1.

Pathways for genes affiliated with Tuberous Sclerosis-1

About this section

Pathways related to Tuberous Sclerosis-1 according to GeneCards Suite gene sharing:

(show top 50)    (show all 57)
idSuper pathwaysScoreTop Affiliating Genes
19.7MTOR, TSC1, TSC2
29.7MTOR, TSC1, TSC2
3
Show member pathways
9.6CDKN1B, MTOR, TSC2
49.3CCL26, MTOR, RPS6KB1
59.3MTOR, PTEN, RPS6KB1
69.3CDKN1B, MTOR, RPS6KB1
79.2PTEN, RHEB, TSC1, TSC2
8
Show member pathways
9.1MTOR, RHEB, TSC1, TSC2
99.1EIF4EBP1, MTOR, TSC1
10
Show member pathways
9.0MTOR, PTEN, RPS6KA1, RPS6KB1
11
Show member pathways
9.0MTOR, PTEN, RAP1A, RPS6KB1
128.9DBH, DCX, GFAP, NF1, SYP
138.8MTOR, PTEN, RHEB, TSC1, TSC2
14
Show member pathways
8.8MTOR, PTEN, RHEB, TSC1, TSC2
158.7CDKN1B, MTOR, RAP1A, RPS6KA1, RPS6KB1
16
Show member pathways
8.7MTOR, RHEB, RPS6KB1, TSC2
17
Show member pathways
8.7EIF4EBP1, MTOR, RPS6KB1
18
Show member pathways
8.6CDKN1B, MTOR, PTEN, RHEB, TSC1, TSC2
19
Show member pathways
8.5CDKN1B, MTOR, RHEB, RPS6KA1, TSC1, TSC2
20
Show member pathways
8.5CDKN1B, MTOR, PTEN, RAP1A, RPS6KA1, RPS6KB1
218.5CDKN1B, EIF4EBP1, MTOR, RPS6KB1
22
Show member pathways
8.5CDKN1B, EIF4EBP1, MTOR, RPS6KB1
23
Show member pathways
8.5EIF4EBP1, MTOR, RPS6KA1, RPS6KB1
24
Show member pathways
8.5EIF4EBP1, MTOR, PTEN, RAP1A, RPS6KA1
258.4EIF4EBP1, MTOR, RAP1A, RPS6KB1
268.3CDKN1B, MTOR, NF1, PTEN, RPS6KB1, TSC1
27
Show member pathways
8.3EIF4EBP1, MTOR, RPS6KB1, TSC1, TSC2
28
Show member pathways
8.3EIF4EBP1, MTOR, RPS6KB1, TSC1, TSC2
298.3MTOR, PTEN, RHEB, RPS6KB1, TSC1, TSC2
30
Show member pathways
8.3EIF4EBP1, MTOR, PTEN, RPS6KB1, TSC2
318.2CDKN1B, EIF4EBP1, MTOR, PTEN, RPS6KB1
328.2MTOR, NF1, PTEN, RAP1A, RHEB, TSC1
33
Show member pathways
8.2EIF4EBP1, MTOR, PTEN, RPS6KA1, RPS6KB1
34
Show member pathways
8.2MTOR, PTEN, RAP1A, RHEB, RPS6KB1, TSC2
358.0EIF4EBP1, MTOR, RAP1A, RPS6KA1, RPS6KB1, TSC2
367.9CDKN1B, EIF4EBP1, MTOR, PTEN, RHEB, TSC2
377.9EIF4EBP1, MTOR, PTEN, RAP1A, RPS6KA1, RPS6KB1
38
Show member pathways
7.9EIF4EBP1, MTOR, RHEB, RPS6KB1, TSC2
397.9EIF4EBP1, MTOR, RHEB, RPS6KB1, TSC2
407.8EIF4EBP1, MTOR, RPL7A, RPS6KB1, TSC1, TSC2
41
Show member pathways
7.7EIF4EBP1, MTOR, RHEB, RPS6KB1, TSC1, TSC2
42
Show member pathways
7.7EIF4EBP1, MTOR, RHEB, RPS6KB1, TSC1, TSC2
43
Show member pathways
7.7EIF4EBP1, MTOR, RHEB, RPS6KB1, TSC1, TSC2
44
Show member pathways
7.7EIF4EBP1, MTOR, PTEN, RHEB, RPS6KB1, TSC2
45
Show member pathways
7.6CCL26, CDKN1B, EIF4EBP1, MTOR, PTEN, RPS6KB1
46
Show member pathways
7.5CDKN1B, EIF4EBP1, MTOR, NF1, PTEN, RPS6KB1
47
Show member pathways
7.5EIF4EBP1, MTOR, RHEB, RPS6KA1, RPS6KB1, TSC1
48
Show member pathways
7.5EIF4EBP1, MTOR, RHEB, RPS6KA1, RPS6KB1, TSC1
49
Show member pathways
7.5EIF4EBP1, MTOR, RHEB, RPS6KA1, RPS6KB1, TSC1
507.5EIF4EBP1, MTOR, RHEB, RPS6KA1, RPS6KB1, TSC1

GO Terms for genes affiliated with Tuberous Sclerosis-1

About this section

Cellular components related to Tuberous Sclerosis-1 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1TSC1-TSC2 complexGO:003359610.1TSC1, TSC2
2neuron projectionGO:00430058.9DCX, PTEN, RAP1A, RPS6KB1, SYP
3cytosolGO:00058295.6CDKN1B, DCX, EIF4EBP1, GFAP, MTOR, NF1
4cytoplasmGO:00057374.9CDKN1B, DBH, DCX, EIF4EBP1, GFAP, MTOR

Biological processes related to Tuberous Sclerosis-1 according to GeneCards Suite gene sharing:

(show all 26)
idNameGO IDScoreTop Affiliating Genes
1maternal behaviorGO:004271110.7DBH, PTEN
2negative regulation of phosphatidylinositol 3-kinase signalingGO:001406710.7PTEN, TSC2
3forebrain morphogenesisGO:004885310.7NF1, PTEN
4anoikisGO:004327610.6MTOR, TSC2
5regulation of cell-matrix adhesionGO:000195210.6NF1, TSC1
6regulation of synaptic transmission, GABAergicGO:003222810.5NF1, PTEN
7negative regulation of macroautophagyGO:001624210.5MTOR, TSC1
8negative regulation of cellular component movementGO:005127110.5CDKN1B, PKHD1
9negative regulation of protein kinase B signalingGO:005189810.3PKHD1, PTEN, TSC2
10negative regulation of cell sizeGO:004579210.3MTOR, PTEN, TSC1
11negative regulation of insulin receptor signaling pathwayGO:004662710.2RPS6KB1, TSC1, TSC2
12positive regulation of endothelial cell proliferationGO:000193810.2CCL26, MTOR, NF1
13cellular response to organic cyclic compoundGO:007140710.2CDKN1B, RAP1A, RPS6KB1
14protein kinase B signalingGO:004349110.2PTEN, RPS6KB1, TSC2
15heart developmentGO:000750710.1NF1, PKD1, PTEN, TSC2
16response to glucoseGO:000974910.1CDKN1B, PTEN, RPS6KB1
17negative regulation of cell proliferationGO:00082859.9CDKN1B, NF1, PTEN, TSC1, TSC2
18response to insulinGO:00328689.9MTOR, RPS6KB1, TSC1
19spinal cord developmentGO:00215109.9MTOR, NF1, PKD1
20response to amino acidGO:00432009.9CDKN1B, MTOR, RPS6KB1
21response to nutrientGO:00075849.8MTOR, PTEN, RPS6KB1
22G1/S transition of mitotic cell cycleGO:00000829.6CDKN1B, EIF4EBP1, RPS6KB1
23visual learningGO:00085429.5DBH, MTOR, NF1
24negative regulation of apoptotic processGO:00430669.5CDKN1B, PKHD1, PTEN, RPS6KA1, RPS6KB1
25cell cycle arrestGO:00070509.2CDKN1B, MTOR, PKD1, RHEB, TSC1, TSC2
26TOR signalingGO:00319299.2EIF4EBP1, MTOR, RPS6KB1

Molecular functions related to Tuberous Sclerosis-1 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein kinase bindingGO:00199018.3CDKN1B, DCX, MTOR, PKD1, PTEN, RHEB

Sources for Tuberous Sclerosis-1

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet